‘Efficacy of anti‐IL ‐23 and anti‐IL ‐17 after adalimumab failure in psoriatic patients’—response to Yu et al.
Journal of the European Academy of Dermatology and Venereology · 2024
DOI: 10.1111/jdv.19517 ↗Kurz gefasst
Leserbrief in der Zeitschrift Journal of the European Academy of Dermatology and Venereology, 2024. Verfasst von L Mastorino und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Sciences, Section of Dermatology, University of Turin, Turin, Italy. Hauptthemen laut MEDLINE: Antirheumatic Agents, Arthritis, Psoriatic, Psoriasis. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 6 Literaturangaben.
Abstract (Originalsprache)
The data that support the findings of this study are available from the corresponding author upon reasonable request.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Medical Sciences, Section of Dermatology, University of Turin, Turin, Italy.
ORCID-Profile: L Mastorino, S Ribero, P Quaglino
Zitieren
APA
Mastorino, L., Ortoncelli, M., Dapavo, P., Ribero, S., & Quaglino, P. (2024). ‘Efficacy of anti‐IL ‐23 and anti‐IL ‐17 after adalimumab failure in psoriatic patients’—response to Yu et al. Journal of the European Academy of Dermatology and Venereology. https://doi.org/10.1111/jdv.19517
Vancouver
Mastorino L, Ortoncelli M, Dapavo P, Ribero S, Quaglino P. ‘Efficacy of anti‐IL ‐23 and anti‐IL ‐17 after adalimumab failure in psoriatic patients’—response to Yu et al. Journal of the European Academy of Dermatology and Venereology. 2024. doi:10.1111/jdv.19517
BibTeX
@article{Mastorino2024,
author = {Mastorino, L and Ortoncelli, M and Dapavo, P and Ribero, S and Quaglino, P},
title = {‘Efficacy of anti‐IL ‐23 and anti‐IL ‐17 after adalimumab failure in psoriatic patients’—response to Yu et al},
journal = {Journal of the European Academy of Dermatology and Venereology},
year = {2024},
doi = {10.1111/jdv.19517}
}
EUVIMED